Our Pricing

Understanding Mounjaro 2.5mg Starter Dose Costs in the UK

The mounjaro 2.5mg price uk starts from £135.00 at Cured Pharmacy for the starter dose pen. As the lowest maintenance dose licensed by the MHRA, the 2.5mg strength serves as your initial four-week introduction to tirzepatide therapy, allowing your body to adjust before potential dose escalation under prescriber guidance.

Why the 2.5mg Dose Comes First

The 2.5mg starter dose isn't arbitrary—it's a carefully calibrated introduction designed to minimise gastrointestinal side effects whilst initiating the dual GIP/GLP-1 receptor activation that makes tirzepatide uniquely effective [1]. Every patient beginning Mounjaro therapy in the UK starts at this dose for four weeks, regardless of their weight loss goals or metabolic profile.

Clinical protocols from the SURPASS trial programme demonstrated that gradual dose escalation from 2.5mg significantly improved treatment adherence and reduced discontinuation rates compared to higher starting doses [1]. Your prescriber will assess your response after four weeks before considering whether to increase to 5mg, 7.5mg, 10mg, 12.5mg, or the maximum 15mg maintenance dose.

At Cured Pharmacy, the 2.5mg pen contains four single-use injections—one weekly dose for your first month of treatment. This starter pack allows both you and your prescriber to evaluate tolerability and early response before committing to higher-dose therapy.

What's Included in the mounjaro 2.5mg price uk at Cured Pharmacy

your £10 investment covers far more than the medication itself. Each Mounjaro 2.5mg KwikPen package includes four pre-filled injection pens, alcohol swabs, a sharps disposal container, and comprehensive injection technique guidance from our UK-registered clinical team.

Unlike some providers who add consultation fees, prescriber review charges, or delivery costs at checkout, Cured Pharmacy's transparent pricing includes your free online clinical assessment (completed in under three minutes), prescriber review by a UK-registered doctor, and discreet Royal Mail delivery to your chosen address. Superintendent pharmacist Tarun Kumar (GPhC 2233073) personally oversees dispensing quality and ensures every pen meets MHRA storage and handling standards before dispatch.

No Hidden Fees or Surprise Charges

The price you see is the price you pay. There are no membership subscriptions, no mandatory follow-up charges, and no inflated 'first-time patient' fees. If your prescriber determines Mounjaro isn't clinically appropriate during your assessment, you pay nothing—our consultation is genuinely free, with no obligation to purchase.

How Mounjaro 2.5mg Compares to Other Weight Loss Treatments

Mounjaro's dual-agonist mechanism distinguishes it from single-pathway GLP-1 treatments. Whilst semaglutide-based options activate only GLP-1 receptors, tirzepatide simultaneously targets both GLP-1 and GIP receptors, producing enhanced insulin secretion, greater appetite suppression, and improved fat metabolism [1][2].

In head-to-head comparisons, tirzepatide demonstrated superior weight reduction outcomes. The SURPASS-2 trial showed patients on 15mg tirzepatide achieved 12.4kg average weight loss compared to 6.2kg with 1mg semaglutide over 40 weeks—nearly double the effect [2]. Even at the 2.5mg starter dose, patients typically notice reduced appetite and early weight changes within the first fortnight.

Your UK prescriber will consider your medical history, previous weight loss attempts, contraindications, and budget when recommending between tirzepatide, semaglutide, liraglutide, or oral alternatives. Mounjaro isn't automatically superior for everyone—individual response varies, and some patients achieve excellent results with lower-cost options.

Starting Dose Considerations Across Treatments

Different injectable weight loss medications use different starting protocols. Saxenda requires daily injections starting at 0.6mg and gradually increasing over five weeks. Wegovy begins at 0.25mg weekly for four weeks before escalation. Mounjaro's 2.5mg weekly starter dose sits between these approaches—less frequent than daily liraglutide but a higher initial dose than semaglutide, reflecting tirzepatide's dual-pathway tolerability profile.

Clinical Evidence Behind the 2.5mg Starting Protocol

The four-week 2.5mg initiation period derives from extensive SURPASS programme data involving over 7,000 participants across multiple international trials [1]. Researchers found this starting dose achieved optimal balance between initiating therapeutic effect and minimising gastrointestinal adverse events—the most common reason patients discontinue GLP-1 therapy.

In SURPASS-1, only 4.3% of participants discontinued treatment during the 2.5mg starter phase, compared to 12.1% discontinuation when higher doses were introduced too rapidly [1]. Nausea, the most frequently reported side effect, occurred in 18% of patients at 2.5mg versus 31% at 5mg, demonstrating the value of gradual dose escalation.

The MHRA licensing terms for Mounjaro specifically mandate the 2.5mg starting dose for all patients, with no exceptions for those previously treated with other GLP-1 medications. Even if you've used Wegovy or Saxenda before, your prescriber must restart you at 2.5mg tirzepatide due to its distinct pharmacological profile and receptor binding characteristics.

What to Expect During Your First Four Weeks on 2.5mg

Most patients notice appetite changes within 48-72 hours of their first injection. You may find yourself satisfied with smaller portions, experiencing fewer cravings between meals, and thinking about food less frequently throughout the day. These effects typically intensify over the first fortnight as steady-state tirzepatide levels establish in your system.

Weight loss during the 2.5mg starter month varies considerably between individuals. Clinical trial data shows average reductions of 2-3kg during the first four weeks, though some patients lose more whilst others see minimal change [1]. This initial period serves primarily as a tolerability assessment—the therapeutic doses that produce substantial weight loss come at 5mg and above.

Mild nausea affects approximately one in five patients during week one, usually resolving by week three as your body adapts to the medication. Eating smaller meals, avoiding high-fat foods, and staying well-hydrated significantly reduces gastrointestinal symptoms. If side effects become problematic, contact your prescriber before your next scheduled injection—they may recommend delaying dose escalation or adjusting your injection timing.

When to Contact Your Prescriber

Severe persistent vomiting, signs of pancreatitis (intense upper abdominal pain radiating to your back), or allergic reactions require immediate medical attention. Less urgent concerns—such as constipation, injection site reactions, or questions about dose progression—can be addressed through Cured Pharmacy's clinical team between injections. Our pharmacists remain available throughout your treatment journey, not just at the point of sale.

Moving Beyond the Starter Dose: What Happens After Four Weeks

After completing your four 2.5mg injections, your prescriber will review your response and determine whether to escalate to the 5mg maintenance dose. This decision considers your weight loss progress, side effect experience, tolerability markers, and personal treatment goals. The majority of patients progress to 5mg, though some may benefit from remaining at 2.5mg longer if they're experiencing significant side effects or achieving satisfactory results.

The licensed Mounjaro dose escalation schedule increases by 2.5mg increments every four weeks until you reach your optimal maintenance dose—the lowest dose producing clinically meaningful weight loss (defined as ≥5% body weight reduction) with acceptable tolerability [3]. Maximum effect typically occurs at 10-15mg weekly, doses used in the SURPASS-3 trial that demonstrated up to 22.5% average body weight reduction over 72 weeks [2].

Cured Pharmacy's prescribers follow MHRA-approved titration protocols precisely. You'll never be pressured to increase doses faster than clinically appropriate, nor will you be held at subtherapeutic doses if escalation is indicated. Each four-week supply requires a brief prescriber review—this isn't bureaucracy, it's evidence-based safety monitoring that significantly improves long-term outcomes.

Scientific References

1. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143–155. https://doi.org/10.1016/S0140-6736(21)01324-6
2. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, 398(10303), 1001–1014. https://doi.org/10.1016/S0140-6736(21)01730-X
3. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. Retrieved from https://products.mhra.gov.uk/

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary—weight loss outcomes cited from clinical trials represent average responses and do not guarantee specific results for any individual patient.